ChromaDex (NASDAQ: CDXC) was a hit on a slightly downbeat Tuesday for the broader market. Its shares raced nearly 10% higher on a price target increase from an analyst.
New York-based investment bank H.C. Wainwright lifted its price target on the stock Tuesday. Actually, that’s an understatement; that level was shot into the sky, to $16 per share from the previous $7. The company maintains its buy recommendation on ChromaDex.